Clinical Trial Update: A Novel Formulation of Bifidobacterium Longum BB536 and Lactobacillus Rhamnosus HN001 With Vitamin B6 on IBS Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a novel probiotic formulation consisting of Bifidobacterium longum BB536, Lactobacillus rhamnosus HN001, and Vitamin B6 for irritable…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Bifidobacterium longum BB536 (Bifidobacterium longum BB536)
• Lactobacillus rhamnosus HN001 (Lactobacillus rhamnosus HN001)
• Pyridoxine (Vitamin B6) (Pyridoxine)

Snippet

Sponsor: University of Bari | Conditions: Irritable Bowel Syndrome | Phase 3 | Status: COMPLETED